Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries

References

• Mackay J, Eriksen M, Shafey O. The Tobacco Atlas, 2nd edn. 2006. Atlanta, GA: American Cancer Society
   Google Scholar
• Gu D, Kelly TN, Wu X, et al. Mortality attributable to smoking in China. N Engl J Med 2009;360:150-9
   PubMed Web of Science ®Google Scholar
• Katanoda K, Marugame T, Saika K, et al. Population attributable fraction of mortality associated with tobacco smoking in Japan: a pooled analysis of three large-scale cohort studies. J Epidemiol 2008;18:251-64
   PubMed Web of Science ®Google Scholar
• Wen CP, Tsai SP, Chen CJ, et al. Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios. Tob Control 2005;14(Suppl 1):i76-80
   PubMedGoogle Scholar
• Jee SH, Yun JE, Park JY, et al. Smoking and cause of death in Korea: 11 years follow-up prospective study. Korean J Epidemiol 2005;27:182-90
   Google Scholar
• Woodward M, Lam TH, Barzi F, et al. Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol 2005;34:1036-45
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71
   PubMed Web of Science ®Google Scholar
• Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8
   PubMed Web of Science ®Google Scholar
• Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-7
   PubMed Web of Science ®Google Scholar
• Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56
   PubMed Web of Science ®Google Scholar
• Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39
   PubMed Web of Science ®Google Scholar
• Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009;14:384-92
   PubMed Web of Science ®Google Scholar
• Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008;32:664-75
   PubMed Web of Science ®Google Scholar
• Fagerström K, Furberg H. A comparison of the Fagerström Test for Nicotine Dependence and smoking prevalence across countries. Addiction 2008;103:841-5
   PubMed Web of Science ®Google Scholar
• Perkins KA. Smoking cessation in women. Special considerations. CNS Drugs 2001;15:391-411
   PubMed Web of Science ®Google Scholar
• Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007;8:1385-402
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Swan GE, Jacob P 3rd, et al. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006;80:457-67
   PubMed Web of Science ®Google Scholar
• Curry S, Marlatt GA, Gordon JR. Abstinence violation effect: validation of an attributional construct with smoking cessation. J Consult Clin Psychol 1987;55:145-9
   PubMed Web of Science ®Google Scholar
• Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010;33:289-301
   PubMed Web of Science ®Google Scholar
• Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805
   PubMed Web of Science ®Google Scholar
• Purvis TL, Nelson LA, Mambourg SE. Varenicline use in patients with mental illness: an update of the evidence. Expert Opin Drug Saf 2010;9:471-82
   PubMed Web of Science ®Google Scholar